Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$117.78 USD
-0.01 (-0.01%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $117.70 -0.08 (-0.07%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 221 - 240 ( 518 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Relevant Abstracts at Upcoming EORTC-NCI-AACR Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Ayvakit Lining Up for Strong Launch in SM, With a First Look at BLU-222
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Approval in AdvSM Expands Ayvakit?s Footprint Beyond GIST; Reit Buy and $135 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for Oral Drugs within Coverage Universe
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department